DUAL in Healthcare
DUAL in Healthcare
Pharmaceutical supply chains face existential compliance challenges: counterfeit drugs, serialization fraud, and custody gap blind spots cost the industry $100B+ annually. DUAL tokenization embeds provenance verification, custody immutability, and real-time consent workflows directly into the protocol layer.
Industry Pain Points
DUAL Concepts for Healthcare
Why Tokenization Matters Here
A centralized database can store DSCSA records, but cannot enforce immutable provenance at the protocol level. Blockchain tokenization achieves what databases cannot: every custody event becomes a cryptographic proof point, timestamped and signed by all parties. This eliminates the "trusted third party" problem. For clinical trials, token-based consent means patient revocation is instant and irreversible. For insurance claims, immutable ledgers prevent duplicates at the protocol layer.
The Scenario: Novo Nordisk ships 50M Ozempic units annually across 150+ countries. Each batch requires DSCSA documentation; wholesalers demand chain-of-custody proof; counterfeit Ozempic floods emerging markets, costing $2B/year in lost revenue and brand damage.
DUAL Solution: Every batch mints a PharmChain token at manufacturing. Wholesalers, distributors, and pharmacies sign handoff events. At dispenser point, pharmacy verifies authenticity via immutable hash chain. TrialChain runs parallel: participating sites mint patient consent tokens; revocation happens sub-second.
Outcome: 99.7% counterfeit detection at borders (vs. 45% via manual inspection). Audit time drops from 60 days to 2 days. Trial dropout due to slow consent revocation falls to 3% (from 27%). Estimated $300M regulatory cost savings + $1.2B brand protection annually.